Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von StockNews.com 

Cyclacel Pharmaceuticals Inc. diskutieren

Cyclacel Pharmaceuticals Inc.

WKN: A2P26W / Symbol: CYCC / Name: Cyclacel Pharmaceuticals Inc. / Aktie / Biotechnologie & medizinische Forschung / Micro Cap /

0,22 €
-2,26 %

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 19,12
Veränderung
Endet am 19.12.24

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) had its price target raised by analysts at Roth Mkm from $16.00 to $21.00. They now have a "buy" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Einschätzung Buy
Rendite (%) -
Kursziel 10,21
Veränderung
Endet am 03.05.25

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) had its price target lowered by analysts at Roth Mkm from $21.00 to $11.00. They now have a "buy" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for CYCC provided by MarketBeat